Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2008 May;51(5):1379-85.
doi: 10.1161/HYPERTENSIONAHA.107.105395. Epub 2008 Mar 31.

Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease

Affiliations
Comparative Study

Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease

Pietro Minuz et al. Hypertension. 2008 May.

Abstract

The aim of the present cross-sectional study was to investigate whether activation of the renin-angiotensin system in renovascular disease affects the cytochrome P450 omega/omega-1 hydroxylase (20-hydroxyeicosatetraenoic acid [20-HETE]) and epoxygenase (epoxyeicosatrienoic acids [EETs]) pathways of arachidonic acid metabolism in vivo, each of which interacts with angiotensin II. Plasma concentration and urinary excretion of 20-HETE and EETs and their metabolites, dihydroxyeicosatrienoic acids, were measured in urine and plasma by mass spectrometry in 10 subjects with renovascular disease, 10 with essential hypertension, and 10 healthy normotensive subjects (control subjects), pair-matched for gender and age. Vascular and renal function were evaluated in all of the subjects. Plasma 20-HETE was highest in subjects with renovascular disease (median: 1.20 ng/mL; range: 0.42 to 1.92 ng/mL) compared with subjects with essential hypertension (median: 0.90 ng/mL; range: 0.40 to 2.17 ng/mL) and control subjects (median: 0.45 ng/mL; range: 0.14 to 1.70 ng/mL; P<0.05). Plasma 20-HETE significantly correlated with plasma renin activity in renovascular disease (r(s)=0.67; n=10; P<0.05). The urinary excretion of 20-HETE was significantly lower in subjects with renovascular disease (median: 12.9 microg/g of creatinine; range: 4.4 to 24.9 microg/g of creatinine) than in control subjects (median: 31.0 microg/g of creatinine; range: 11.9 to 102.8 microg/g of creatinine; P<0.01) and essential hypertensive subjects (median: 35.9 microg/g of creatinine; range: 14.0 to 72.5 microg/g of creatinine; P<0.05). Total plasma EETs were lowest, as was the ratio of plasma EETs to plasma dihydroxyeicosatrienoic acids, an index of epoxide hydrolase activity, in renovascular disease (ratio: 2.4; range: 1.2 to 6.1) compared with essential hypertension (ratio: 3.4; range: 1.5 to 5.6) and control subjects (ratio: 6.8; range: 1.4 to 18.8; P<0.01). In conclusion, circulating levels of 20-HETE are increased and those of EETs are decreased in renovascular disease, whereas the urinary excretion of 20-HETE is reduced. Altered cytochrome P450 arachidonic acid metabolism may contribute to the vascular and tubular abnormalities of renovascular disease.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Statistically significant differences were observed in plasma concentration (A) and urinary excretion (B and C) of 20-HETE between patients with RVD and healthy control subjects. n.s. indicates not significant.
Figure 2
Figure 2
Plasma concentration of EETs (A) and the sum of plasma EETs and plasma DHETs (C), as well as EETs:DHETs ratio (D) were lowest in patients with RVD. Plasma concentrations of DHET (B) were not statistically different in patients with RVD, EH, and healthy controls. n.s. indicates not significant.
Figure 3
Figure 3
Statistically significant correlation was observed between plasma 20-HETE and PRA either when all of the studied subjects were considered (n=30) or when only data from patients with RVD were analyzed. Black dots indicate patients with RVD (n=10).

Similar articles

Cited by

References

    1. McGiff JC, Quilley J. 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens. 2001;10:231–237. - PubMed
    1. Sarkis A, Lopez B, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids in hypertension. Curr Opin Nephrol Hypertens. 2004;13:205–214. - PubMed
    1. Elbekai RH, El-Kadi AOS. Cytochrome P450 enzymes: central players in cardiovascular health and disease. Pharmacol Ther. 2006;112:564–587. - PubMed
    1. Garovic VD, Textor SC. Renovascular hypertension and ischemic nephropathy. Circulation. 2005;112:1362–1374. - PubMed
    1. Quilley J, McGiff JC. Multiple roles of eicosanoids in blood pressure regulation. In: Lipp GYH, Hall J, editors. Comprehensive Hypertension. Philadelphia, PA: Mosby Elsevier; 2007. pp. 377–395.

Publication types

Substances